These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 17396109)

  • 1. Primer: establishing a clinical trial unit - regulations and infrastructure.
    Fleischmann R
    Nat Clin Pract Rheumatol; 2007 Apr; 3(4):234-9. PubMed ID: 17396109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trials are short, disease long: measuring drug utility beyond clinical trials.
    Luggen ML
    J Rheumatol; 2004 Feb; 31(2):205-6. PubMed ID: 14760785
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical study with a new phenylbutazone preparation in rheumatology].
    Marmont A; Rossi F
    Clin Ter; 1972 Oct; 63(1):17-51. PubMed ID: 4566104
    [No Abstract]   [Full Text] [Related]  

  • 5. Establishing pan-European clinical trials: regulatory compliance and other practical considerations.
    Grienenberger A
    J Biolaw Bus; 2004; 7(4):58-63. PubMed ID: 15675097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performing trials in children with rheumatic diseases: comment on the editorial by Lehman.
    Ruperto N; Martini A; Lovell DJ; Giannini EH; ;
    Arthritis Rheum; 2008 Apr; 58(4):1201-2; author reply 1203. PubMed ID: 18383366
    [No Abstract]   [Full Text] [Related]  

  • 7. Are better endpoints and better design of clinical trials needed?
    Fransen J; van Riel PL
    Best Pract Res Clin Rheumatol; 2004 Feb; 18(1):97-109. PubMed ID: 15123040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing the efficiency of clinical trials of antimicrobials: the scientific basis of substantial evidence of effectiveness of drugs.
    Powers JH
    Clin Infect Dis; 2007 Sep; 45 Suppl 2():S153-62. PubMed ID: 17683020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proceedings of the 5th annual perspectives in rheumatic diseases.
    Furst DE; Mandell B; Calabrese LH; Cather JC; Clauw DJ; Deodhar A; Kremer JM; Lewiecki EM; McMahon M; Ritchlin CT
    Semin Arthritis Rheum; 2013 Dec; 43(3):416-9. PubMed ID: 24326035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The draft FDA guideline on non-inferiority clinical trials: a critical review from European pharmaceutical industry statisticians.
    Huitfeldt B; Hummel J;
    Pharm Stat; 2011; 10(5):414-9. PubMed ID: 21932294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics in the rheumatic diseases.
    Cronstein BN
    Bull NYU Hosp Jt Dis; 2006; 64(1-2):16-9. PubMed ID: 17121484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical trial primer: historical perspective and modern implementation.
    Karsh LI
    Urol Oncol; 2012; 30(4 Suppl):S28-32. PubMed ID: 22795078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Setting the research agenda for future clinical trials on the use of biologics in rheumatology.
    Silman A; Rudkin S; Walley T
    Rheumatology (Oxford); 2011 Aug; 50(8):1356-7. PubMed ID: 21118870
    [No Abstract]   [Full Text] [Related]  

  • 14. [Attitude of patient associations to clinical trials of new drugs].
    Tybkjaer HW; Witte L; Johannessen MB
    Ugeskr Laeger; 2003 Apr; 165(16):1688-90. PubMed ID: 12756833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the efficacy and safety of rheumatic disease treatments: obstacles and proposed solutions.
    Felson DT
    Arthritis Rheum; 2003 Jul; 48(7):1781-7. PubMed ID: 12847670
    [No Abstract]   [Full Text] [Related]  

  • 16. Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working Party. Outcome Measures in Rheumatology.
    Gazarian M; Tugwell P; Boers M; Bombardier C; Brooks P; Day R; Strand V; Wells G
    J Rheumatol; 1999 Jan; 26(1):207-9. PubMed ID: 9918265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials in molecular imaging: the importance of following the protocol.
    Trembath L; Opanowski A;
    J Nucl Med Technol; 2011 Jun; 39(2):63-9. PubMed ID: 21565960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The history of the use of sulphasalazine in rheumatology.
    Amos RS
    Br J Rheumatol; 1995 Nov; 34 Suppl 2():2-6. PubMed ID: 8535643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are biologics more effective than classical disease-modifying antirheumatic drugs?
    Nurmohamed MT; Dijkmans BA
    Arthritis Res Ther; 2008; 10(5):118. PubMed ID: 18828888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ankylosing spondylitis antirheumatic drug trials. II. Tables for calculating sample size for clinical trials.
    Bellamy N; Buchanan WW; Esdaile JM; Fam AG; Kean WF; Thompson JM; Wells GA; Campbell J
    J Rheumatol; 1991 Nov; 18(11):1709-15. PubMed ID: 1787493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.